(-)-Epigallocatechin gallate inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts

KENJI KATO1,2, TAKANOBU OTSUKA1, SEIJI ADACHI2, RIE MATSUSHIMA-NISHIWAKI2, HIDEHITO NATSUME1,2, OSAMU KOZAWA2 and HARUHIKO TOKUDA1,2,3

1Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601; 2Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu 501-1194; 3Department of Clinical Laboratory, National Center for Geriatrics and Gerontology, Aichi 474-8511, Japan

Received September 8, 2010; Accepted December 24, 2010

DOI: 10.3892/mmr.2011.421

Abstract. It is recognized that catechin possesses beneficial properties for bone metabolism. We previously revealed that triiodothyronine (T3)-stimulated P38 MAP kinase, but not p44/p42 MAP kinase, is involved in the synthesis of osteocalcin in osteoblast-like MC3T3-E1 cells. In the present study, we investigated the effect of (-)-epigallocatechin gallate (EGCG), the predominant green tea polyphenol, on the synthesis of osteocalcin in MC3T3-E1 cells. EGCG significantly suppressed T3-stimulated osteocalcin synthesis. The inhibitory effect of EGCG was dose-dependent in the range of 3 to 30 µM. On the other hand, T3-induced phosphorylation of p38 MAP kinase was not affected by EGCG. EGCG profoundly inhibited T3-stimulated transcriptional activity. These results strongly suggest that EGCG suppresses T3-stimulated osteocalcin synthesis upstream of the transcriptional level in osteoblast-like MC3T3-E1 cells.

Introduction

Polyphenolic compounds in foods have beneficial properties to human beings. It is generally known that, among the polyphenolic compounds, flavonoids possess antioxidative, anti-inflammatory and antitumor effects (1,2). Green tea contains several polyphenolic ingredients, also called catechins (2). (-)-Epigallocatechin gallate (EGCG) is the most abundant catechin and a major bioactive component (2). Bone metabolism is mainly regulated by two functional cells, osteoblasts and osteoclasts (3). The former are responsible for bone formation and the latter for bone resorption. The resorption of pre-existing bone by osteoclasts and the formation of new bone by osteoblasts are strictly coordinated to maintain moderate bone mass. The adult skeleton is continuously renewed via bone remodeling. In bone metabolism, accumulating evidence suggests that catechins suppress bone resorption, while supporting osteoblastic functions (4,5). As for osteoblasts, it has been revealed that catechin stimulates alkaline phosphatase activity, a mature osteoblast phenotype, and reduces apoptosis in osteoblast-like MC3T3-E1 cells (4). EGCG has been reported to inhibit osteoclastogenesis in osteoclast-like cell cultures (6–8).

Keywords: catechin, triiodothyronine, osteocalcin, mitogen-activated protein kinase, osteoblast
effects of the thyroid hormone are exerted through binding to its specific intracellular receptors and the subsequent activation of the expression of the gene network (15). As for the signaling of the thyroid hormone, it has been reported that the activation of p44/p42 mitogen-activated protein (MAP) kinase, which belongs to the MAP kinase superfamily (16), is involved in the regulation of thyroid hormone-inhibited p53 transcriptional activity in human kidney cells (17). In our previous studies (18,19), we found that p38 MAP kinase, but not p44/p42 MAP kinase, is involved in T\(_3\)-stimulated osteocalcin synthesis in osteoblast-like MC3T3-E1 cells, and that the adenyl cyclase-cAMP system has an inhibitory role in osteocalcin synthesis via suppression of the p38 MAP kinase activation. In the present study, we investigated the effect of EGCG on T\(_3\)-stimulated osteocalcin synthesis in osteoblast-like MC3T3-E1 cells. The results indicate that EGCG suppresses T\(_3\)-stimulated osteocalcin synthesis upstream of the transcriptional level in these cells.

**Materials and methods**

**Materials.** T\(_3\) was obtained from Sigma Chemical Co. (St. Louis, MO, USA). EGCG was obtained from Calbiochem-Novabiochem Co. (La.Jolla, CA, USA). The mouse osteocalcin enzyme-linked immunosorbent assay (ELISA) was obtained from Biomedical Technologies Inc. (Stoughton, MA, USA). Phospho-specific p38 MAP kinase antibodies and p38 MAP kinase antibodies were obtained from Cell Signaling, Inc. (Beverly, MA, USA). An ECL Western blotting detection system was obtained from GE Healthcare (Buckinghamshire, UK). Other materials and chemicals were obtained from commercial sources. T\(_3\) was dissolved in 0.1 M NaOH.

**Cell culture.** Cloned osteoblast-like MC3T3-E1 cells derived from newborn mouse calvaria (20) were maintained as previously described (21). Briefly, the cells were cultured in \(\alpha\)-minimum essential medium (\(\alpha\)-MEM) containing 10% fetal calf serum (FCS) at 37°C in a humidified atmosphere of 5% CO\(_2\) and 95% air. The cells were seeded into 35-mm (5x10\(^4\) cells/dish) or 90-mm (2x10\(^5\) cells/dish) diameter dishes in \(\alpha\)-MEM containing 10% FCS. The cultured cells were pretreated with 30 µM of EGCG for 60 min and then stimulated by 10 nM of T\(_3\) for the indicated periods. Each value represents the mean ± SEM of triplicate determinations. Similar results were obtained with two additional and different cell preparations. *p<0.05, compared to the value of control; **p<0.05 compared to the value of T\(_3\) alone.

**Luciferase reporter assay.** A reporter plasmid, pDR4 (thyroid hormone response element)-Luc was purchased from Stratagene (La Jolla, CA, USA). The cultured cells were treated with or without 30 µM EGCG at 4 h after transfection. After the EGCG pre-treatment (60 min), the cells were stimulated by 10 nM T\(_3\) or vehicle for 48 h. Transient transfection with the pDR4-Luc reporter plasmid (1 µg/dish) and measurement of the luciferase activity of the cell lysates were performed using UniFector transfection reagent (B-Bridge International, Mountain View, CA, USA) and a dual luciferase reporter assay system (Promega Corp., Madison, WI, USA), respectively. The cells were cotransfected with pRL-CMV (Renilla luciferase; 0.1 µg/dish) as an internal standard to normalize transfection efficiency.

**Statistical analysis.** Data were analyzed by ANOVA followed by the Bonferroni method for multiple comparisons between pairs, and p<0.05 was considered significant. All data are presented as the mean ± SEM of triplicate determinations. Each experiment was repeated three times with similar results.

**Results**

**Effect of EGCG on the T\(_3\)-stimulated synthesis of osteocalcin in MC3T3-E1 cells.** We previously reported that T\(_3\) time-dependently stimulates the synthesis of osteocalcin in osteoblast-like MC3T3-E1 cells, and that the effect of T\(_3\) is dose-dependent in the range of 1 pM and 10 nM (18). In

![Figure 1. Effect of EGCG on the T\(_3\)-stimulated synthesis of osteocalcin in MC3T3-E1 cells. The cultured cells were pretreated with 30 µM of EGCG (●) or vehicle (○) for 60 min and then stimulated by 10 nM of T\(_3\) for the indicated periods. Each value represents the mean ± SEM of triplicate determinations. Similar results were obtained with two additional and different cell preparations. *p<0.05, compared to the value of control; **p<0.05 compared to the value of T\(_3\) alone.](image)
In the present study, we first examined the effect of EGCG on T<sub>3</sub>-stimulated osteocalcin synthesis. EGCG, which alone had little effect on osteocalcin levels, significantly reduced the T<sub>3</sub>-stimulated synthesis of osteocalcin (Fig. 1). The inhibitory effect of EGCG on osteocalcin synthesis was dose-dependent in the range of 10 to 30 mM (Fig. 2). EGCG (30 mM) caused an ~60% reduction in the T<sub>3</sub> effect.

**Effect of EGCG on the T<sub>3</sub>-induced phosphorylation of p38 MAP kinase in MC3T3-E1 cells.** In our previous studies (18,24), we revealed that T<sub>3</sub> induces both the activation of p44/p42 MAP kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells, and that p38 MAP kinase, but not p44/p42 MAP kinase, takes part at least in the T<sub>3</sub>-stimulated synthesis of osteocalcin. In order to clarify whether p38 MAP kinase activation is involved in the EGCG effect on T<sub>3</sub>-stimulated osteocalcin synthesis, we examined the effect of EGCG on the T<sub>3</sub>-induced phosphorylation of p38 MAP kinase. However, EGCG did not attenuate the T<sub>3</sub>-induced phosphorylation levels of p38 MAP kinase (Fig. 3).

**Effect of EGCG on T<sub>3</sub>-induced transactivation activity of thyroid hormone response element in MC3T3-E1 cells.** We further examined the effect of EGCG on T<sub>3</sub>-stimulated activation of thyroid hormone response element in MC3T3-E1 cells using a Luciferase reporter assay. We confirmed that T<sub>3</sub> significantly elevated the transactivation activity of the thyroid hormone response element (Fig. 4, column 2), while EGCG markedly decreased T<sub>3</sub>-stimulated transactivation activity (Fig. 4, column 3 compared to column 2).

**Discussion**

In the present study, we demonstrated that EGCG, a predominant polyphenolic component in green tea (4,5), significantly reduced T<sub>3</sub>-stimulated osteocalcin synthesis in osteoblast-like MC3T3-E1 cells. We then investigated the mechanisms of EGCG suppression of osteocalcin synthesis. It is generally known that the MAP kinase superfamily plays a crucial role in a variety of cellular functions, including proliferation, differentiation and survival, in numerous types of cells (16). Three major MAP kinases – p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) – are known to be central elements used by mammalian cells to transduce the diverse messages (16). Regarding the signaling of thyroid hormone, it has been revealed that thyroid hormone inhibits p53 transcriptional activity through the activation of p44/p42 MAP kinase in human kidney cells (17). We previously revealed that T<sub>3</sub> activates p44/p42 MAP kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells and that p38 MAP kinase, but not p44/p42 MAP kinase, plays a role in T<sub>3</sub>-stimulated osteocalcin synthesis (18). Thus, we investigated...
whether p38 MAP kinase is involved in the suppressive effect of EGCG on T3-stimulated osteocalcin synthesis in osteoblast-like MC3T3-E1 cells. However, EGCG failed to affect the T3-induced phosphorylation of p38 MAP kinase. Therefore, it seems unlikely that EGCG functions at a point upstream of p38 MAP kinase in the synthesis of osteocalcin stimulated by T3.

In general, it is recognized that the effects of thyroid hormone are exerted through its binding to specific intracellular receptors, and that the receptor-hormone complex subsequently activates the expression of the gene network, since the thyroid hormone belongs to the nuclear receptor superfamily (15). In the present study, we revealed that EGCG significantly suppresses the T3-elevated transactivation activity of the thyroid hormone response element. Therefore, it is likely that the inhibitory effect of EGCG on T3-stimulated osteocalcin synthesis is due to the suppression of transcriptional events in osteoblast-like MC3T3-E1 cells. Further investigation is required to clarify the detailed mechanism of catechin underlying the suppression of osteocalcin synthesis in osteoblasts.

Osteocalcin produced specifically in mature osteoblasts is stored in bone matrix, binding strongly to hydroxyapatite, and is then released into circulation (9). It has been established that osteocalcin is one of the markers of bone metabolism. Recent accumulating evidence suggests that osteocalcin controls glucose utilization and energy expenditure by acting on muscle to increase insulin sensitivity and glucose uptake, on adipocytes to increase adiponectin, and on pancreatic β-cells to increase insulin secretion (10,11). It is currently recognized that osteocalcin is a bone hormone regulating energy metabolism. Here, we revealed that T3-stimulated osteocalcin synthesis is markedly suppressed by EGCG in osteoblast-like MC3T3-E1 cells. Based on these results, it is likely that catechin may modulate energy metabolism through the regulation of osteocalcin synthesis in osteoblasts. In the present study, we found that EGCG suppresses T3-stimulated osteocalcin synthesis at a dose over 10 μM. It has been reported that the pharmacokinetics of EGCG in human volunteers taking a single dosage of 1,600 mg/day shows a rapid absorption with a maximum plasma concentration of 11.08 μM, and that the time to reach maximum plasma concentration is 2.2 h with the terminal elimination half-life ranging between 1.9 and 4.6 h (25). It appears likely that the concentration of EGCG used in the present study is achievable in vivo. Further investigation is required to elucidate the exact roles of catechin in bone and energy metabolism.

In conclusion, our results strongly suggest that EGCG suppresses T3-stimulated osteocalcin synthesis at a point upstream of the transcriptional level in osteoblasts.

Acknowledgements

We are very grateful to Yoko Kawamura for her skillful technical assistance. This investigation was supported in part by a Grant-in-Aid for Scientific Research (19591042) from the Ministry of Education, Science, Sports and Culture of Japan, the Foundation for Growth Science, and Research Grants for Longevity Sciences (21A-4, 21A-22) from the Ministry of Health, Labour and Welfare of Japan.

References